Zai Lab Ltd (ZLAB) — SEC Financial Statements & Analysis

Zai Lab Ltd (ZLAB) is a pharmaceutical preparations company, incorporated in E9. Zai Lab Ltd trades on Nasdaq as: ZLAB. Zai Lab Ltd (ZLAB)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06. Based on that filing, Zai Lab Ltd carries a market cap of $2.12B, a P/E ratio of -11.28x, a P/B ratio of 3.50x, a P/S ratio of 4.75x, an enterprise value of $1.75B, and an EV/EBITDA multiple of -7.06x. On profitability, it posts a gross margin of 143.75%, an operating margin of -59.09%, a net margin of -42.11%, a Return on Equity (ROE) of -26.91%, a Return on Assets (ROA) of -16.81%, and a Return on Invested Capital (ROIC) of -107.98%. Per share, it reports EPS of $-1.69, diluted EPS of $-1.69, free cash flow per share of $-1.25, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 5.04% year-over-year, net income growth of -11.44% year-over-year, and EPS growth of -13.42% year-over-year. On the balance sheet, it maintains a current ratio of 2.13x, a quick ratio of 1.84x, working capital of $485.45M, a debt-to-equity ratio of 0.77x, a debt ratio of 0.44, an interest coverage ratio of -44.13x, free cash flow of $-139.57M (TTM), and net debt of $-369.42M. Figures sourced from SEC EDGAR.

Market Cap

$2.12B

P/E TTM

-11.28x

EPS TTM

$-1.69

P/B TTM

3.50x

ROE TTM

-26.91%

ROA TTM

-16.81%

Debt To Equity

0.77x

Free Cash Flow TTM

$-139.57M

Net Revenue TTM Growth 1Y

5.04%

Data as of 2026-06-30 · Source: SEC EDGAR